Ambulatory Care Self-Assessment Program (ACSAP) (Cert #L259046)
ACPE Numbers: Various – see listing below Release Date: March 17, 2025 Expiration Dates: March 17, 2026 Activity Type: Application-based CE Credits: 18.5 contact hours (BPS and ACPE) Activity Fee: $88 (ASHP member); $132 (non-member)
Activity Overview
This course is intended for board certified pharmacists in need of recertification credit and is designed based on the content outline developed by Board of Pharmacy Specialties (BPS). The course consists of 10 learning modules (see table below) and provides up to 18.5 contact hours of continuing pharmacy education and/or recertification credit.
Learners will be required to review the content and complete the associated online assessments. The learner must be able to correctly answer the questions based upon their interpretation of the content, as well as “baseline specialty specific knowledge and/or easily retrievable information.” For purposes of this course, “baseline specialty specific knowledge and/or easily retrievable information” is defined as product labeling and well-established standards of practice in the specialty practice.
These activities are part of the ACCP and ASHP professional development program for BCACP recertification approved by the BPS.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.
Board certified pharmacists are eligible to receive up to 18.5 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.
ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.
ACCP and ASHP are approved by BPS as a provider for the recertification of BCACP.
Learning Activity
Passing Score
Credit Information
Recorded Webcast: Chronic Obstructive Pulmonary Disease
Recorded Webcast: Chronic Obstructive Pulmonary Disease ACPE #:0217-9999-25-041-H01-P
Distinguish risk factors and goals of therapy for patients with chronic obstructive pulmonary disease (COPD).
Assess patients with COPD and classify their risk stratification into A, B, or E categories.
Apply knowledge of nonpharmacologic techniques for COPD when educating patients.
Develop an appropriate pharmacologic regimen for patients with chronic stable COPD (initial and follow-up therapy).
Evaluate strategies to improve patient access to COPD medications and streamline regimens.
Discover new therapies on the horizon for patients with COPD.
Updates in Asthma Management ACPE #: 0217-9999-25-048-H01-P
Distinguish the most likely asthma phenotype based on symptoms, patient characteristics, and laboratory values.
Classify asthma severity based on current symptoms and future risk of asthma exacerbations.
Evaluate individual patient characteristics when choosing an appropriate inhaled drug delivery device.
Develop an appropriate pharmacotherapy treatment plan for a patient with newly diagnosed asthma, symptoms of worsening asthma, and difficult-to-treat asthma.
Case Series: Upper Respiratory Tract Infections in Adults ACPE #: 0217-9999-25-049-H01-P
Classify an upper respiratory tract infection (URTI) given an adult patient’s signs, symptoms, risk factors, medical history, and laboratory results.
Design treatment plans, including nonpharmacologic therapy, nonprescription medications, and pharmacotherapy, for adult patients with URTI.
Evaluate the evidence, clinical appropriateness, and safety of complementary and integrative therapies to prevent or treat a URTI.
Given a study assessing a URTI, evaluate the research design and biostatistical methods.
HIV Preexposure Prophylaxis ACPE #: 0217-9999-25-044-H01-P
Evaluate a patient’s risk of acquiring HIV and determine whether the patient is a candidate for preexposure prophylaxis (PrEP) initiation.
Design a patient-centered treatment plan for HIV PrEP.
Distinguish patients who are candidates for doxycycline postexposure prophylaxis (doxy PEP) and provide patient-centered counseling.
Assess methods by which pharmacists can expand and enhance HIV prevention initiatives.
Case Series: Long COVID ACPE #: 0217-9999-25-045-H01-P
Analyze the epidemiology of Long coronavirus disease 2019 (Long COVID).
Develop an understanding of how Long COVID is diagnosed.
Assess risk factors for Long COVID.
Demonstrate an understanding of the complexities surrounding the clinical manifestations of Long COVID.
Synthesize the current research on the potential mechanisms of Long COVID.
Assess the current knowledge on the prevention and treatment of Long COVID.
Assess gaps in current knowledge related to pathogenesis, diagnosis, and management of Long COVID.
Opioid Use Disorder ACPE #: 0217-9999-25-047-H01-P
Evaluate the current epidemiologic trends in prescription opioid misuse and illicit opioid use, including overdose and use disorders.
Distinguish opioid use neurobiology with initial use and with prolonged use as it applies to the development of an opioid use disorder (OUD) and return to use risk.
Apply universal screening techniques for substance use disorders and compare the screening tools available.
Develop an individualized, patient-centered treatment plan for OUD by evaluating appropriate medication and psychosocial intervention options.
Classify the clinical pharmacology, efficacy, and safety of methadone, buprenorphine, and naltrexone in treating OUD.
Distinguish unique differences in treating adolescents, young adults, pregnant and postpartum patients, and individuals with co-occurring use disorders with medications for OUD.
Develop a comprehensive harm reduction plan for an individual with OUD considering their unique recovery journey.
Classify recent changes to legislation and regulation of OUD treatment.
Epilepsy ACPE #: 0217-9999-25-043-H01-P
Distinguish between seizure types, epilepsy types, and epilepsy syndromes.
Evaluate current pharmacotherapy options for the treatment of epilepsy.
Evaluate current non-pharmacotherapy options for the treatment of epilepsy.
Analyze safety considerations for anti-seizure medications.
In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ACCP and ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company.
An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience.
The following persons in control of this activity’s content have relevant financial relationships:
Consultancies: Jennifer D. Goldman (Sanofi; Novo Nordisk; Lilly); Diana Isaacs (Sanofi; Lifescan; Medtronic)
Stock Ownership: Kylie N. Barnes (Inovio Pharmaceuticals); Jennifer D. Goldman (Lilly; Novo Nordisk; Abbott); Alexandra Herman (Citius Pharmaceuticals; Soligenix; Zomedica)
Activities consist of educational materials, assessments, and activity evaluations. In order to receive continuing pharmacy education credit, learners must:
Complete the attestation statement
Review all content
Complete and pass the assessments
Complete the evaluations
Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.
